<DOC>
	<DOCNO>NCT00898027</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood urine laboratory patient cancer receive epidermal growth factor receptor inhibitor may help doctor understand effect epidermal growth factor receptor inhibitor magnesium level body . PURPOSE : This laboratory study look effect epidermal growth factor receptor inhibitor magnesium homeostasis patient cancer .</brief_summary>
	<brief_title>Effect Epidermal Growth Factor Receptor Inhibitors Magnesium Homeostasis Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect EGFR inhibitor magnesium homeostasis patient cancer . OUTLINE : This pilot study . Patients undergo blood urine sample collection baseline 2 , 4 , 8 week treatment . After finish treatment , patient follow periodically 10 week .</detailed_description>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Diagnosis malignancy Planning receive therapy inhibitor EGFR pathway ( either clinical trial may monotherapy combined therapy ) Normal serum magnesium level Glomerular filtration rate â‰¥ 60 mL/min No severe underlie renal dysfunction Normal serum potassium calcium level No history primary secondary hyperparathyroidism PRIOR CONCURRENT THERAPY : No prior EGFR pathway inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>